Brodalumab
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, ss.58-60, 2022 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 56
- Basım Tarihi: 2022
- Doi Numarası: 10.4274/turkderm.galenos.2022.01643
- Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.58-60
- Anahtar Kelimeler: Anti-IL-17RA, brodalumab, psoriasis
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Erciyes Üniversitesi Adresli: Evet
Özet
Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75 response has been achieved in 82-84% of the patients at week 12. It was shown to be effective also in generalized pustular and erythrodermic psoriasis. As with other IL-17 inhibitors, brodalumab should be used with caution in patients with inflammatory bowel disease.